title: It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma.
authors.affiliation: Elena Elimova, University of Texas MD Anderson Cancer Center, Houston, TX; Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Mary Mulcahy, Feinberg School of Medicine, Lurie Comprehensive Cancer Center, Chicago, IL; Daniel V. Catenacci, University of Chicago, Chicago, IL; Mariela A. Blum, University of Texas MD Anderson Cancer Center, Houston, TX; Khaldoun Almhanna, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; J. Randolph Hecht, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA; and Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Elena
authors.initials: E
authors.lastname: Elimova
authors.affiliation: Elena Elimova, University of Texas MD Anderson Cancer Center, Houston, TX; Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Mary Mulcahy, Feinberg School of Medicine, Lurie Comprehensive Cancer Center, Chicago, IL; Daniel V. Catenacci, University of Chicago, Chicago, IL; Mariela A. Blum, University of Texas MD Anderson Cancer Center, Houston, TX; Khaldoun Almhanna, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; J. Randolph Hecht, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA; and Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Yelena Y
authors.initials: YY
authors.lastname: Janjigian
authors.affiliation: Elena Elimova, University of Texas MD Anderson Cancer Center, Houston, TX; Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Mary Mulcahy, Feinberg School of Medicine, Lurie Comprehensive Cancer Center, Chicago, IL; Daniel V. Catenacci, University of Chicago, Chicago, IL; Mariela A. Blum, University of Texas MD Anderson Cancer Center, Houston, TX; Khaldoun Almhanna, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; J. Randolph Hecht, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA; and Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Mary
authors.initials: M
authors.lastname: Mulcahy
authors.affiliation: Elena Elimova, University of Texas MD Anderson Cancer Center, Houston, TX; Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Mary Mulcahy, Feinberg School of Medicine, Lurie Comprehensive Cancer Center, Chicago, IL; Daniel V. Catenacci, University of Chicago, Chicago, IL; Mariela A. Blum, University of Texas MD Anderson Cancer Center, Houston, TX; Khaldoun Almhanna, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; J. Randolph Hecht, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA; and Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Daniel V
authors.initials: DV
authors.lastname: Catenacci
authors.affiliation: Elena Elimova, University of Texas MD Anderson Cancer Center, Houston, TX; Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Mary Mulcahy, Feinberg School of Medicine, Lurie Comprehensive Cancer Center, Chicago, IL; Daniel V. Catenacci, University of Chicago, Chicago, IL; Mariela A. Blum, University of Texas MD Anderson Cancer Center, Houston, TX; Khaldoun Almhanna, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; J. Randolph Hecht, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA; and Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Mariela A
authors.initials: MA
authors.lastname: Blum
authors.affiliation: Elena Elimova, University of Texas MD Anderson Cancer Center, Houston, TX; Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Mary Mulcahy, Feinberg School of Medicine, Lurie Comprehensive Cancer Center, Chicago, IL; Daniel V. Catenacci, University of Chicago, Chicago, IL; Mariela A. Blum, University of Texas MD Anderson Cancer Center, Houston, TX; Khaldoun Almhanna, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; J. Randolph Hecht, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA; and Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Khaldoun
authors.initials: K
authors.lastname: Almhanna
authors.affiliation: Elena Elimova, University of Texas MD Anderson Cancer Center, Houston, TX; Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Mary Mulcahy, Feinberg School of Medicine, Lurie Comprehensive Cancer Center, Chicago, IL; Daniel V. Catenacci, University of Chicago, Chicago, IL; Mariela A. Blum, University of Texas MD Anderson Cancer Center, Houston, TX; Khaldoun Almhanna, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; J. Randolph Hecht, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA; and Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: J Randolph
authors.initials: JR
authors.lastname: Hecht
authors.affiliation: Elena Elimova, University of Texas MD Anderson Cancer Center, Houston, TX; Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Mary Mulcahy, Feinberg School of Medicine, Lurie Comprehensive Cancer Center, Chicago, IL; Daniel V. Catenacci, University of Chicago, Chicago, IL; Mariela A. Blum, University of Texas MD Anderson Cancer Center, Houston, TX; Khaldoun Almhanna, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; J. Randolph Hecht, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA; and Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Jaffer A
authors.initials: JA
authors.lastname: Ajani
mesh_terms: D000230:Adenocarcinoma; D000068818:Cetuximab; D015251:Epirubicin; D004938:Esophageal Neoplasms; D004943:Esophagogastric Junction; D006801:Humans; D013274:Stomach Neoplasms
chemical_list: D015251:Epirubicin; D000068818:Cetuximab